July/August #181 : Triple Crown Win for HIV? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


How Congress Can Cure AIDS

Rolling in the Deep

From the Editor

AIDS Apartheid


Letters- July/August 2012


The Cure Hunter

What You Need to Know

Keeping HIV at Bay in Cuba?

Lawsuits Against Two Eateries Are a Whopper of a Story

Schools Across the Globe Deserve Dunce Caps for HIV Discrimination

Helping the Playas Play Safe

We Believe in Magic

We Hear You

Dealing With Discrimination in the Workplace

POZ Survey Says

Do Pills Equal Pleasure?

What Matters to You

LGBT Rights

Treatment News

How Poverty Helps Spread HIV

Altering Cells Might Boost HIV Control

Triple Crown Win for HIV?

Trauma Center

Comfort Zone

Life Support

POZ Heroes

An Army of Heroes

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July / August 2012

Triple Crown Win for HIV?

by Laura Whitehorn

In May, advisory committees of the U.S. Food and Drug Administration (FDA) recommended approval of three new ways to test, prevent and treat HIV. PrEP for prevention, the “Quad” pill for treatment, and an over-the-counter, at-home HIV test for, well, testing. At press time, final decisions on approvals of all three are pending. The FDA panels considered these new tools strictly in terms of what scientific data indicated about their potential benefits. The discussion about how best to wield these tools in the real world continues.

Here’s a snapshot of the starting gate:

For Prevention: Truvada as Pre-Exposure Prophylaxis (PrEP)
First out was the idea of using daily doses of the HIV drug Truvada (tenofovir plus emtricitabine) to prevent HIV-negative people from acquiring the virus. It will be the first drug approved as a form of oral pre-exposure prophylaxis, or PrEP, and it must be taken daily and used with condoms and other safer-sex measures.

Committee members voted, though not unanimously, to approve PrEP for men who have sex with men or for the negative partner in a stable relationship with a positive person. By an even slimmer margin they gave the go-ahead to PrEP for other groups.

Among the issues under debate: Will HIV-negative people be able to stick to the rigorous daily dosing schedule necessary for Truvada to work as PrEP? How will possible side effects be monitored and managed? Is it ethical to provide pills to high-risk HIV-negative people in the United States when 750,000 HIV-positive Americans are not currently receiving meds?
For Treatment: the Quad
The advisory panel also recommended approval of a four-drug all-in-one pill to treat HIV. The tablet, nicknamed the “Quad,” would be for first-time HIV drug takers. Taken once daily, it contains two experimental compounds, elvitegravir and cobicistat, plus already-FDA-approved HIV drugs Viread (tenofovir) and Emtriva (emtricitabine).

For Testing: the OraQuick In-Home HIV Test
Another panel recommended approval for OraSure’s oral swab–based rapid in-home HIV test. Despite data showing that the test is less sensitive than other HIV tests (missing as many as seven positive diagnoses per 100), the panel recommended approval on the grounds that potential benefits to public health outweigh these risks.

Search: U.S. Food and Drug Administration, FDA, Pre-Exposure Prophylaxis, PrEP, Quad pill, Gilead, Truvada, OraQuick In-Home HIV Test

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.